Consensus Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
8.97 USD -0.44% Intraday chart for Theravance Biopharma, Inc. +0.11% -20.20%

Evolution of the average Target Price on Theravance Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c66bfb0b9dff93ba0109f36f11ae38af.n1nqqKa4d36ipwSuU2UZUaYZsha_-ldaNSgVw2-G2TA.yz-O3pPCQhbnk0HBKlF1JOQux1jUgxoFdHtWhB7ZsVftF8fMlM4tNNDRMA~91d2bc8de63851877b5a0a707ff18cf1
HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating MT
SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating MT
Theravance Biopharma Rises After SVB Securities Initiates Outperform Rating MT
SVB Securities Initiates Theravance Biopharma at Outperform With $12 Price Target MT
HC Wainwright Adjusts Theravance Biopharma's Price Target to $12 From $8, Reiterates Buy Rating MT
JPMorgan Upgrades Theravance Biopharma to Neutral From Underweight, Lifts Price Target to $12 From $7 MT
THERAVANCE BIOPHARMA : Needham Downgrades Theravance Biopharma to Hold From Buy MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating MT
THERAVANCE BIOPHARMA : Morgan Stanley Adjusts Theravance Biopharma's Price Target to $10 from $14, Keeps Underweight Rating MT
THERAVANCE BIOPHARMA : SVB Leerink Cuts Price Target on Theravance Biopharma to $10 From $29, Keeps Outperform Rating MT
THERAVANCE BIOPHARMA : HC Wainwright Slashes Price Target on Theravance Biopharma to $8 From $21, Keeps Buy Rating MT
ANALYST RECOMMENDATIONS : Activision Blizzard, Beyond Meat, Britvic, Las Vegas Sans, Unilever... Our Logo
THERAVANCE BIOPHARMA : JPMorgan Downgrades Theravance Biopharma to Underweight From Overweight, Adjusts Price Target to $7 From $17 MT
ANALYST RECOMMENDATONS : Asos, Beazley, Factset, Hiscox, Next... Our Logo
THERAVANCE BIOPHARMA : Morgan Stanley Downgrades Theravance Biopharma to Underweight From Overweight, Lowers PT to $14 From $27 MT
THERAVANCE BIOPHARMA : Evercore ISI Adjusts Theravance Biopharma PT to $21 From $30, Maintains Outperform Rating MT
THERAVANCE BIOPHARMA : JPMorgan Adjusts Theravance Biopharma's Price Target to $23 From $27, Maintains Overweight Rating MT
THERAVANCE BIOPHARMA : Baird Adjusts Theravance Biopharma's Price Target to $10 From $20, Maintains Neutral Rating MT
Today on Wall Street: A new central bank theory Our Logo
THERAVANCE BIOPHARMA : SVB Leerink Adjusts Price Target on Theravance Biopharma to $29 From $37, Maintains Outperform Rating MT
THERAVANCE BIOPHARMA : Needham Adjusts Theravance Biopharma's Price Target to $18 From $32, Keeps Buy Rating MT
THERAVANCE BIOPHARMA : HC Wainwright Adjusts Theravance Biopharma's Price Target to $21 From $32, Maintains Buy Rating MT
THERAVANCE BIOPHARMA : BofA Securities Adjusts Theravance Biopharma's Price Target to $14 From $20, Keeps Underperform Rating MT
THERAVANCE BIOPHARMA : Cowen Cuts Theravance Biopharma to Market Perform From Outperform, Price Target to $14 From $42 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
8.97 USD
Average target price
14 USD
Spread / Average Target
+56.08%
High Price Target
20 USD
Spread / Highest target
+122.97%
Low Price Target
10 USD
Spread / Lowest Target
+11.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Theravance Biopharma, Inc.

HC Wainwright
SVB Securities LLC
JPMorgan Chase
SVB Leerink
Baird
Morgan Stanley
Needham & Co.
Cowen
BofA Securities
Evercore ISI
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings